Printable Version

Home > Drug Related News > New indication for Aldara

New indication for Aldara

The FDA has recently approved Aldara for the treatment of actinic keratosis.1 Aldara is also indicated for the treatment of external genital and perianal warts in children > 12 years of age and adults. Some unlabeled indications for Aldara include treatment of common warts and basal cell carcinoma. 2

Actinic keratosis is a dermatological condition characterized by the presence of red, scaly lesions. These lesions usually develop after age 40 and are caused by prolonged, excessive exposure to ultraviolet light. Since actinic keratosis can progress to squamous cell carcinoma, elimination of these lesions is essential.3

Actinic keratosis can be treated several ways. Some non-pharmacological treatments include cryosurgery, skin peels with 35% trichloroacetic acid, Co2 laser therapy and dermabrasion. Topical 5-flourouracil (Efudex®) and topical diclofenac (Solaraze®) are some pharmacological treatments currently used for actinic keratoses.2

Aldara is an immune response modifier thought to act by stimulating the immune system. Aldara is applied twice a week for 4 months when treating actinic keratosis. The cream should be applied at night and washed off after 6 to 10 hours.1 Some frequently occurring side effects of Adara include erythema, itching, erosion, burning and edema. Only treating lesions and minimizing the area of application will help reduce the risk of side effects.2

Morgan Watkins, PharmD. Candidate

References:

Pharmacist’s Letter

Lexi-Comp’s Drug Information Handbook

Griffiths 5 Minute Clinical Consult